Minimally Invasive Therapies Are Reshaping Knee Osteoarthritis Care
Knee osteoarthritis remains one of the most common chronic musculoskeletal disorders in adults, driven by progressive articular cartilage degeneration, synovial inflammation, pain, stiffness, and loss of function. The condition affects one in five people over 40 years old, a prevalence figure that explains why conservative and procedural options continue to draw intense clinical attention. In this 2024 review, investigators examined traditional and newer minimally invasive approaches for patients with knee osteoarthritis, while also assessing how artificial intelligence may help speed diagnosis and support treatment selection.
The review spans a space where bedside care often begins with symptom control but quickly runs into the limits of oral medication, rehabilitation, and activity modification. When pain persists and function declines, clinicians increasingly consider image-guided injections or percutaneous procedures that target either the inflamed joint environment or the nociceptive pathways feeding pain. The article places three familiar intra-articular strategies—corticosteroids, hyaluronic acid, and platelet-rich plasma—alongside two more recent interventions, genicular artery embolization and genicular nerve ablation.
Pain relief in osteoarthritis is never just about symptom suppression. Each intervention addresses a different node in the disease process, whether by dampening synovitis, altering joint lubrication and viscoelasticity, reducing inflammatory neovascularity, or interrupting sensory signaling from the knee capsule. That mechanistic diversity is one reason the therapeutic field has expanded so quickly, even as the evidence remains uneven.
Intra-Articular Injections Still Dominate First-Line Procedural Care
Among the studied interventions, intra-articular injections remain the most widely used minimally invasive option in routine practice. Corticosteroid injections can provide short-term anti-inflammatory benefit, especially when synovitis and effusion contribute to pain. Their appeal lies in rapid onset and procedural simplicity, yet repeated use raises longstanding concerns about durability and the narrow window of benefit relative to chronic disease burden.
Hyaluronic acid occupies a different therapeutic niche. Rather than directly suppressing inflammation, it is intended to improve the mechanical properties of synovial fluid and support joint lubrication. For some patients, that approach may translate into symptom improvement over a longer time horizon, but the evidence base remains mixed and recommendations vary across medical societies. The review reflects that inconsistency rather than smoothing it over.
Platelet-rich plasma has gained popularity because of its biologic rationale. By delivering a concentrated platelet-derived milieu into the joint, it is positioned as a regenerative or anti-inflammatory strategy rather than a purely symptomatic one. Even so, studies have not produced a uniform answer on who benefits most, how to standardize preparation methods, or how long any clinical effect persists. Variation in protocol remains a major reason results diverge across the literature.
Genicular Artery Embolization Targets Inflammation at the Vascular Level
Genicular artery embolization is among the most novel entries in the procedural armamentarium for knee osteoarthritis. The logic is biologically coherent: inflamed osteoarthritic tissue often develops abnormal neovascularity, and embolization aims to reduce the hypervascular inflammatory supply that can perpetuate pain. By interrupting this vascular contribution, the procedure seeks to quiet the inflammatory microenvironment without entering the joint space itself.
Preliminary evidence supports GAE as a potential minimally invasive therapy for patients with moderate to severe disease. Its emergence matters because it offers a distinct path for patients who have failed medication and standard injections yet are not immediate surgical candidates. Still, the technique remains earlier in its evidentiary arc than many established interventions, and patient selection will likely determine how broadly it can be used in practice.
Genicular Nerve Ablation Interrupts Pain Transmission Rather Than Joint Pathology
Genicular nerve ablation takes a different approach altogether. Instead of targeting inflammation or joint fluid dynamics, it disrupts sensory nerve signaling from the knee. For patients whose pain burden is out of proportion to mechanical findings or who experience persistent pain despite prior conservative measures, this pathway offers a rational nonoperative alternative.
The procedure is especially relevant in moderate to severe disease, where pain control can become the main barrier to mobility, sleep, and participation in rehabilitation. By reducing nociceptive input, nerve ablation may help patients move more comfortably and preserve function while delaying or avoiding more invasive surgery. The review identifies preliminary evidence in favor of efficacy, but the field still needs stronger comparative data to clarify duration of benefit, repeatability, and the profiles most likely to respond.
A single procedure can change pain reporting without changing the joint itself.
Mixed Evidence Continues to Shape Society Recommendations
The review is careful in its assessment of the overall evidence base. For the intra-articular injections covered, support is mixed, and formal medical society recommendations vary in strength. That variability reflects not only differences in study design and endpoints, but also the biological heterogeneity of osteoarthritis itself. A patient with inflammatory synovitis, another with predominant mechanical degeneration, and a third with advanced structural disease may each respond differently to the same treatment.
This is where practical clinical decision-making becomes more selective. A treatment with modest average benefit can still be valuable when matched to the right phenotype, but broad generalizations are hard to defend in a disease as heterogeneous as knee osteoarthritis. Procedural choice often depends on symptom severity, imaging findings, prior treatment response, and the patient’s willingness to accept a procedure with uncertain long-term durability.
Artificial Intelligence Could Shorten the Diagnostic Path
The review also examines artificial intelligence as a tool for streamlining diagnosis and potentially informing treatment selection. In routine care, diagnosis of knee osteoarthritis often combines symptoms, physical examination, and imaging, yet delays can still occur when clinical findings are ambiguous or when early disease is difficult to classify. AI-driven systems may help clinicians recognize patterns more quickly and support more consistent decision-making.
The promise here is not replacement of clinical judgment. It is better triage, faster recognition, and improved alignment between phenotype and therapy. If AI can assist in identifying patients more likely to respond to a given minimally invasive approach, it could help reduce trial-and-error prescribing and direct patients to the right procedure sooner. The review presents evidence that this is a plausible future use, though not a settled standard of care.
What the Review Leaves Open for Daily Practice
For now, the practical message is one of cautious expansion rather than wholesale substitution. Corticosteroids, hyaluronic acid, and platelet-rich plasma remain familiar tools with uneven evidence and variable guideline support. Genicular artery embolization and genicular nerve ablation look increasingly attractive for moderate to severe disease, especially when conventional management has failed, but the evidence is still preliminary.
The field needs better head-to-head trials, more standardized protocols, and longer follow-up to determine which patients truly benefit and how long those benefits last. Without that clarity, procedural enthusiasm will continue to outpace certainty in some settings. The review closes on a concrete gap: knee osteoarthritis care is moving toward more personalized intervention, but the evidence base has not yet caught up with the pace of innovation.